bright-field pla detection reagent Search Results


bright field pla  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology bright field pla
Tamoxifen <t>disrupts</t> <t>ESR1-p53</t> interaction in breast cancer patient tumors ESR1-p53 interaction in tamoxifen-treated versus untreated tumor tissue was assayed by bright-field <t>PLA</t> with primary antibodies against ERα (HC20) and p53 (DO1) (Santa Cruz Biotechnology) on breast cancer patient TMA. (A) Representative images of tumor tissue IHC for ERα & p53 and their corresponding PLA interactions are shown. (B) Quantification of PLA scores for ERα-p53 interaction in tamoxifen-treated vs. untreated tumor is shown on the right panels. Scale bar – PLA, 20 μm and IHC, 100 μm. Data are represented as mean ± SEM. Statistical significance was determined by a Student’s t test. p = 0.0053. See also <xref ref-type=Table S4 . " width="250" height="auto" />
Bright Field Pla, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bright-field+pla+detection+reagent/Polylactic+acid/pmc11166704-156-22-33
Average 93 stars, based on 1 article reviews
bright field pla - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
duolink® pla brightfield kit duo092012  (Merck KGaA)
90
Merck KGaA duolink® pla brightfield kit duo092012
Tamoxifen <t>disrupts</t> <t>ESR1-p53</t> interaction in breast cancer patient tumors ESR1-p53 interaction in tamoxifen-treated versus untreated tumor tissue was assayed by bright-field <t>PLA</t> with primary antibodies against ERα (HC20) and p53 (DO1) (Santa Cruz Biotechnology) on breast cancer patient TMA. (A) Representative images of tumor tissue IHC for ERα & p53 and their corresponding PLA interactions are shown. (B) Quantification of PLA scores for ERα-p53 interaction in tamoxifen-treated vs. untreated tumor is shown on the right panels. Scale bar – PLA, 20 μm and IHC, 100 μm. Data are represented as mean ± SEM. Statistical significance was determined by a Student’s t test. p = 0.0053. See also <xref ref-type=Table S4 . " width="250" height="auto" />
Duolink® Pla Brightfield Kit Duo092012, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bright-field+pla+detection+reagent/duolink+++pla+brightfield+kit+duo092012/pm37257316-130-12-17
Average 90 stars, based on 1 article reviews
duolink® pla brightfield kit duo092012 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
bx53 widefield light microscope  (Olympus)
99
Olympus bx53 widefield light microscope
Tamoxifen <t>disrupts</t> <t>ESR1-p53</t> interaction in breast cancer patient tumors ESR1-p53 interaction in tamoxifen-treated versus untreated tumor tissue was assayed by bright-field <t>PLA</t> with primary antibodies against ERα (HC20) and p53 (DO1) (Santa Cruz Biotechnology) on breast cancer patient TMA. (A) Representative images of tumor tissue IHC for ERα & p53 and their corresponding PLA interactions are shown. (B) Quantification of PLA scores for ERα-p53 interaction in tamoxifen-treated vs. untreated tumor is shown on the right panels. Scale bar – PLA, 20 μm and IHC, 100 μm. Data are represented as mean ± SEM. Statistical significance was determined by a Student’s t test. p = 0.0053. See also <xref ref-type=Table S4 . " width="250" height="auto" />
Bx53 Widefield Light Microscope, supplied by Olympus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bright-field+pla+detection+reagent/BX53+System+Microscope/pmc09954582-88-13-12
Average 99 stars, based on 1 article reviews
bx53 widefield light microscope - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

Image Search Results


Tamoxifen disrupts ESR1-p53 interaction in breast cancer patient tumors ESR1-p53 interaction in tamoxifen-treated versus untreated tumor tissue was assayed by bright-field PLA with primary antibodies against ERα (HC20) and p53 (DO1) (Santa Cruz Biotechnology) on breast cancer patient TMA. (A) Representative images of tumor tissue IHC for ERα & p53 and their corresponding PLA interactions are shown. (B) Quantification of PLA scores for ERα-p53 interaction in tamoxifen-treated vs. untreated tumor is shown on the right panels. Scale bar – PLA, 20 μm and IHC, 100 μm. Data are represented as mean ± SEM. Statistical significance was determined by a Student’s t test. p = 0.0053. See also <xref ref-type=Table S4 . " width="100%" height="100%">

Journal: iScience

Article Title: ESR1 and p53 interactome alteration defines mechanisms of tamoxifen response in luminal breast cancer

doi: 10.1016/j.isci.2024.109995

Figure Lengend Snippet: Tamoxifen disrupts ESR1-p53 interaction in breast cancer patient tumors ESR1-p53 interaction in tamoxifen-treated versus untreated tumor tissue was assayed by bright-field PLA with primary antibodies against ERα (HC20) and p53 (DO1) (Santa Cruz Biotechnology) on breast cancer patient TMA. (A) Representative images of tumor tissue IHC for ERα & p53 and their corresponding PLA interactions are shown. (B) Quantification of PLA scores for ERα-p53 interaction in tamoxifen-treated vs. untreated tumor is shown on the right panels. Scale bar – PLA, 20 μm and IHC, 100 μm. Data are represented as mean ± SEM. Statistical significance was determined by a Student’s t test. p = 0.0053. See also Table S4 .

Article Snippet: Figure 4 Tamoxifen disrupts ESR1-p53 interaction in breast cancer patient tumors ESR1-p53 interaction in tamoxifen-treated versus untreated tumor tissue was assayed by bright-field PLA with primary antibodies against ERα (HC20) and p53 (DO1) (Santa Cruz Biotechnology) on breast cancer patient TMA. (A) Representative images of tumor tissue IHC for ERα & p53 and their corresponding PLA interactions are shown. (B) Quantification of PLA scores for ERα-p53 interaction in tamoxifen-treated vs. untreated tumor is shown on the right panels.

Techniques:

Journal: iScience

Article Title: ESR1 and p53 interactome alteration defines mechanisms of tamoxifen response in luminal breast cancer

doi: 10.1016/j.isci.2024.109995

Figure Lengend Snippet:

Article Snippet: Figure 4 Tamoxifen disrupts ESR1-p53 interaction in breast cancer patient tumors ESR1-p53 interaction in tamoxifen-treated versus untreated tumor tissue was assayed by bright-field PLA with primary antibodies against ERα (HC20) and p53 (DO1) (Santa Cruz Biotechnology) on breast cancer patient TMA. (A) Representative images of tumor tissue IHC for ERα & p53 and their corresponding PLA interactions are shown. (B) Quantification of PLA scores for ERα-p53 interaction in tamoxifen-treated vs. untreated tumor is shown on the right panels.

Techniques: Recombinant, Amplification, In Situ, Polymer, Protein Extraction, Protease Inhibitor, Staining, Bicinchoninic Acid Protein Assay, Software, Spectrophotometry, Immunohistochemistry